1、亚洲干眼协会中国分会, 海峡两岸医药卫生交流协会眼科学专
业委员会眼表与泪液病学组, 中国医师协会眼科医师分会眼表
与干眼学组. 中国干眼专家共识:定义和分类(2020年)[ J]. 中
华眼科学杂志, 2020, 56(6): 418-422. 
 China Branch of Asian Dry Eye Association. Ophthalmology Group 
of Ophthalmology Committee of Cross Strait Medical and Health 
Exchange Association. Eye surface and dry Ophthalmology Group, 
Ophthalmologist Branch, Chinese Medical Association. China dry 
eye expert consensus: definition and classification (2020)[ J]. Chinese 
Journal of Ophthalmology, 2020, 56(6): 418-422.亚洲干眼协会中国分会, 海峡两岸医药卫生交流协会眼科学专
业委员会眼表与泪液病学组, 中国医师协会眼科医师分会眼表
与干眼学组. 中国干眼专家共识:定义和分类(2020年)[ J]. 中
华眼科学杂志, 2020, 56(6): 418-422. 
 China Branch of Asian Dry Eye Association. Ophthalmology Group 
of Ophthalmology Committee of Cross Strait Medical and Health 
Exchange Association. Eye surface and dry Ophthalmology Group, 
Ophthalmologist Branch, Chinese Medical Association. China dry 
eye expert consensus: definition and classification (2020)[ J]. Chinese 
Journal of Ophthalmology, 2020, 56(6): 418-422.
							  
                                  
                                      
								  2、Honkanen RA, Huang L, Xie G, et al. Phosphosulindac is efficacious 
in an improved concanavalin A-based rabbit model of chronic dry eye 
disease[ J]. Transl Res, 2018, 198: 58-72.Honkanen RA, Huang L, Xie G, et al. Phosphosulindac is efficacious 
in an improved concanavalin A-based rabbit model of chronic dry eye 
disease[ J]. Transl Res, 2018, 198: 58-72.
							  
                                  
                                      
								  3、中华医学会眼科学分会角膜病学组. 干眼临床诊疗专家共识
(2013年)[ J]. 中华眼科杂志, 2013, 49(1): 73-75. 
 Corneal Diseases Group of Chinese Society of Ophthalmology. Expert 
consensus on clinical diagnosis and treatment of dry eye (2013)[ J]. 
Chinese Journal of Ophthalmology, 2013, 49(1): 73-75.中华医学会眼科学分会角膜病学组. 干眼临床诊疗专家共识
(2013年)[ J]. 中华眼科杂志, 2013, 49(1): 73-75. 
 Corneal Diseases Group of Chinese Society of Ophthalmology. Expert 
consensus on clinical diagnosis and treatment of dry eye (2013)[ J]. 
Chinese Journal of Ophthalmology, 2013, 49(1): 73-75.
							  
                                  
                                      
								  4、Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology 
report[ J]. Ocul Surf, 2017, 15(3): 334-365.Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology 
report[ J]. Ocul Surf, 2017, 15(3): 334-365.
							  
                                  
                                      
								  5、Bron A J, de Paiva CS, Chauhan SK , et al. TFOS DE WS II pathophysiology report[ J]. Ocul Surf, 2017, 15(3): 438-510.Bron A J, de Paiva CS, Chauhan SK , et al. TFOS DE WS II pathophysiology report[ J]. Ocul Surf, 2017, 15(3): 438-510.
							  
                                  
                                      
								  6、Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive 
summary[ J]. Ocul Surf, 2017, 15(4): 802-812.Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive 
summary[ J]. Ocul Surf, 2017, 15(4): 802-812.
							  
                                  
                                      
								  7、Lekhanont K, Sathianvichitr K, Pisitpayat P, et al. Association between 
the levels of prostaglandin E2 in tears and severity of dry eye[ J]. Int J 
Ophthalmol, 2019, 12(7): 1127-1133.Lekhanont K, Sathianvichitr K, Pisitpayat P, et al. Association between 
the levels of prostaglandin E2 in tears and severity of dry eye[ J]. Int J 
Ophthalmol, 2019, 12(7): 1127-1133.
							  
                                  
                                      
								  8、Domenichiello AF, Wilhite BC, Keyes GS, et al. A dose response study 
of the effect of prostaglandin E2 on thermal nociceptive sensitivity[ J]. 
Prostaglandins Leukot Essent Fatty Acids, 2017, 126: 20-24.Domenichiello AF, Wilhite BC, Keyes GS, et al. A dose response study 
of the effect of prostaglandin E2 on thermal nociceptive sensitivity[ J]. 
Prostaglandins Leukot Essent Fatty Acids, 2017, 126: 20-24.
							  
                                  
                                      
								  9、Li YJ, Luo LJ, Harroun SG, et al. Synergistically dual-functional nano 
eye-drops for simultaneous anti-inflammatory and anti-oxidative 
treatment of dry eye disease[ J]. Nanoscal, 2019, 11(12): 5580-5594.Li YJ, Luo LJ, Harroun SG, et al. Synergistically dual-functional nano 
eye-drops for simultaneous anti-inflammatory and anti-oxidative 
treatment of dry eye disease[ J]. Nanoscal, 2019, 11(12): 5580-5594.
							  
                                  
                                      
								  10、Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and 
therapy report[ J]. Ocul Surf, 2017, 15(3): 575-628.Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and 
therapy report[ J]. Ocul Surf, 2017, 15(3): 575-628.
							  
                                  
                                      
								  11、赵展琳. 干眼与神经调节异常相关研究进展[ J]. 中华实验眼科
杂志, 2020, 38(3): 233-237. 
 ZHAO ZL. Research Progress on the relationship between dry eye 
and abnormal neuromodulation[ J]. Chinese Journal of Experimental 
Ophthalmology, 2020, 38(3): 233-237.赵展琳. 干眼与神经调节异常相关研究进展[ J]. 中华实验眼科
杂志, 2020, 38(3): 233-237. 
 ZHAO ZL. Research Progress on the relationship between dry eye 
and abnormal neuromodulation[ J]. Chinese Journal of Experimental 
Ophthalmology, 2020, 38(3): 233-237.
							  
                                  
                                      
								  12、Mukhopadhyay S, Heinz E, Porreca I, et al. Loss of IL-10 signaling in 
macrophages limits bacterial killing driven by prostaglandin E2[ J]. J 
Exp Med, 2020, 217(2): e20180649.Mukhopadhyay S, Heinz E, Porreca I, et al. Loss of IL-10 signaling in 
macrophages limits bacterial killing driven by prostaglandin E2[ J]. J 
Exp Med, 2020, 217(2): e20180649.
							  
                                  
                                      
								  13、Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and 
classification report[ J]. Ocul Surf, 2017, 15(3): 276-283.Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and 
classification report[ J]. Ocul Surf, 2017, 15(3): 276-283.
							  
                                  
                                      
								  14、Shim J, Park C, Lee HS, et al. Change in prostaglandin expression levels 
and synthesizing activities in dry eye disease[ J]. Ophthalmology, 2012, 
119(11): 2211-2219.Shim J, Park C, Lee HS, et al. Change in prostaglandin expression levels 
and synthesizing activities in dry eye disease[ J]. Ophthalmology, 2012, 
119(11): 2211-2219.
							  
                                  
                                      
								  15、Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye 
syndrome[ J]. Arch Ophthalmol, 2000, 118(9): 1264-1268.Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye 
syndrome[ J]. Arch Ophthalmol, 2000, 118(9): 1264-1268.
							  
                                  
                                      
								  16、Nelson JD, Craig JP, Akpek EK, et al. TFOS DEWS II Introduction[ J]. 
Ocul Surf, 2017, 15(3): 269-275.Nelson JD, Craig JP, Akpek EK, et al. TFOS DEWS II Introduction[ J]. 
Ocul Surf, 2017, 15(3): 269-275.
							  
                                  
                                      
								  17、黎颖莉, 刘祖国, 邓应平, 等. 干眼临床诊疗的新认识及研究的新
方向[ J]. 中华实验眼科杂志, 2020, 38(3), 161-164. 
 LI YL, LIU ZG, DENG YP, et al. New understanding and 
research direction of clinical diagnosis and treatment of dry eye[ J]. 
Chinese Journal of Experimental Ophthalmology, 2020, 38(3): 161-164.黎颖莉, 刘祖国, 邓应平, 等. 干眼临床诊疗的新认识及研究的新
方向[ J]. 中华实验眼科杂志, 2020, 38(3), 161-164. 
 LI YL, LIU ZG, DENG YP, et al. New understanding and 
research direction of clinical diagnosis and treatment of dry eye[ J]. 
Chinese Journal of Experimental Ophthalmology, 2020, 38(3): 161-164.